
LIFECORE BIOMEDICAL INC
LFCRNASDAQTrading Snapshot
- Day Range
- $4.78 โ $4.85
- 52-Week Range
- $3.63 โ $8.98
- Volume
- $2.61B
- Avg Volume
- $3.22B
- Shares Outstanding
- 37.5M
- Next Earnings
- Sep 1, 2026
Fundamentals Snapshot
- Annual Revenue
- $34M
- Last Q Revenue
- $34M
- P/E Ratio
- โ
- P/S Ratio
- 1.1x
- EPS (TTM)
- $-1.18
- Dividend Yield
- โ
Why Investors Own LFCR
- โHigh-growth profile โ revenue up +48.4% YoY with expanding US Equity exposure.
- โHealthy economics โ 53% gross margin and 25% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About LIFECORE BIOMEDICAL INC
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Otter Score Breakdown
โAnalyst Ratings
โLatest News & Updates

Lifecore Biomedical, Inc. (LFCR) Q2 2026 Earnings Call Transcript
Lifecore Biomedical, Inc. (LFCR) Q2 2026 Earnings Call August 5, 2026 8:00 AM EDTCompany ParticipantsPaul Josephs - President, CEO & DirectorRyan Lake -...
Lifecore Biomedical Q2 EPS $(0.19) Beats $(0.22) Estimate, Sales $34.200M Beat $32.016M Estimate
Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 24 percent increase over losses of $(0.25) per share from
Lifecore Biomedical Affirms FY2026 Sales Guidance of $120.000M-$125.000M vs $122.176M Est
Lifecore Biomedical (NASDAQ:LFCR) affirms FY2026 sales outlook from $120.000 million-$125.000 million to $120.000 million-$125.000 million vs $122.176 million estimate.